Ultragenyx stockholders approve amended 2023 incentive plan and elect directors at annual meeting

Ultragenyx Pharmaceutical Inc.

Class II directors Dunsire, Narachi, and Sanders elected with over 66M votes each for terms until 2027.
Amended 2023 Incentive Plan approved: 51.9M for, 22.3M against; adds 8.5M shares plus prior plan rollover shares.
Ernst & Young ratified as independent auditor for FY2024 with 77.2M votes for (98.2% of votes cast).
Advisory vote on executive compensation passed with 54.8M for vs 19.3M against; 4.3M broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.